|
David R. Parkinson, M.D. joined Nodality in September of 2007. Previously, he served as senior vice president, Oncology Research and Development since joining Biogen Idec in March 2006, where he oversaw all oncology discovery research efforts and the development of the oncology pipeline.
Dr. Parkinson joined Biogen Idec from Amgen where he was Vice President, Oncology Development. Previously, he held several senior oncology positions at Novartis. During his tenure at both companies, Dr. Parkinson was responsible for clinical development activities leading to a series of successful global drug registrations for important cancer therapeutics, including Gleevec, Femara, Zometa, Kepivance, and Vectibix, among others.
Dr. Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch, then as Acting Associate Director of the Cancer Therapy Evaluation Program before leaving for Novartis. He had previously also held academic positions at the M.D. Anderson Cancer Center, University of Texas and New England Medical Center, Tufts University School of Medicine.
He received his M.D. from the University of Toronto Faculty of Medicine in 1977, with Internal medicine and Hematology/Oncology training in Montreal at McGill University and then in Boston at New England Medical Center. Currently, Dr. Parkinson serves on the National Cancer Policy Forum of the Institute of Medicine. He is a past Chairman of the FDA Biologics Advisory Committee and is a recipient of the FDA’s Cody Medal. He currently is a member of the FDA’s Science Board. He was recently elected to the Board for Directors of the American Association of Cancer Research, and continues to serve as Chairperson of the AACR Finance Committee. | 